24/7 Market News Snapshot 17 September, 2024 – Capricor Therapeutics Inc (NASDAQ:CAPR)

September 17, 2024

DENVER, Colo., 17 September, 2024 (247marketnews.com) – (NASDAQ:CAPR) are discussed in this article.
Capricor Therapeutics Inc. (NASDAQ:CAPR) is experiencing a substantial surge in trading activity, with shares opening at $4.86 and currently reaching $5.08, representing a 15.19% increase from a previous closing of $4.41. This notable shift indicates robust investor confidence, evidenced by a trading volume of 1.39 million shares. Analysts suggest monitoring technical indicators, including the Relative Strength Index (RSI), for potential overbought conditions, while a support level appears to be forming around $4.50. The current momentum may attract additional investors as market sentiment remains positive.

In a strategic move that underscores its commitment to addressing rare diseases, Capricor has announced a significant partnership with Nippon Shinyaku Co., Ltd. for the commercialization of deramiocel, a groundbreaking therapy aimed at treating Duchenne muscular dystrophy (DMD). This collaboration not only enhances Capricor’s reach in the European market but also promises to deliver critical therapeutic options to patients affected by this severe genetic disorder.

The agreement entails a substantial equity investment of approximately $15 million at a 20% premium, along with an upfront payment of $20 million expected upon closing a definitive agreement in the fourth quarter of 2024. This collaboration could yield substantial financial milestones totaling up to $715 million and a double-digit revenue share from product sales following the anticipated launch of deramiocel.

Dr. Linda Marbán, CEO of Capricor, expressed enthusiasm about this partnership, highlighting its importance in the company’s mission to deliver transformative treatments for DMD. The funds will bolster Capricor’s capabilities to meet increasing demand and support its commercialization initiatives extending into 2026. The collaboration with Nippon Shinyaku aims to leverage their distribution expertise, allowing Capricor to concentrate on advancing deramiocel toward regulatory approval in international markets, thereby strengthening its position in the biotechnology sector dedicated to innovative solutions for rare diseases.

Related news for (CAPR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.